fda compounding semaglutide crackdown news today 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Compounded Semaglutide & Tirzepatide 2025:
Description
A call placed to the clinic was not returned
No clinically significant QTc prolongation has been observed with orforglipron in thorough QT studies or clinical trial ECG monitoring
Evaluation of the Degradation and Metabolic Effects of the Gut Peptide Xenin on Insulin Secretion, Glycaemic Control and Satiety
While primarily designed to assess renal outcomes, the trial also demonstrated significant cardiovascular benefits
[DOI] [PMC free article] [PubMed] [Google Scholar] 166.Shandilya A, et al
